Trial Profile
A Phase II Trial of Pazopanib in Von Hippel-Lindau Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Von Hippel-Lindau disease
- Focus Adverse reactions; Therapeutic Use
- 14 Mar 2024 Status changed from active, no longer recruiting to completed.
- 15 Sep 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 15 Sep 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.